Leibman Financial Services Inc. Grows Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Leibman Financial Services Inc. raised its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 100.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,509 shares of the company's stock after purchasing an additional 31,872 shares during the period. Leibman Financial Services Inc. owned 0.07% of Progyny worth $1,096,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Nordea Investment Management AB lifted its holdings in shares of Progyny by 5.8% in the 4th quarter. Nordea Investment Management AB now owns 185,042 shares of the company's stock worth $3,175,000 after purchasing an additional 10,203 shares in the last quarter. Central Pacific Bank Trust Division lifted its holdings in shares of Progyny by 89.8% in the fourth quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company's stock valued at $229,000 after purchasing an additional 6,270 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock worth $759,000 after purchasing an additional 7,003 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in shares of Progyny by 67.7% in the 3rd quarter. Tidal Investments LLC now owns 60,722 shares of the company's stock worth $1,018,000 after buying an additional 24,507 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several research reports. JPMorgan Chase & Co. restated a "neutral" rating and set a $17.00 price target (down previously from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Leerink Partners cut their price target on Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research note on Thursday, September 19th. Truist Financial reissued a "hold" rating and issued a $19.00 price target (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Jefferies Financial Group cut their price target on Progyny from $31.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, September 19th. Finally, JMP Securities cut shares of Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th. Nine analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Progyny presently has an average rating of "Hold" and a consensus target price of $25.00.

Progyny Trading Down 1.3 %

Shares of PGNY traded down $0.26 during mid-day trading on Tuesday, reaching $20.04. The company's stock had a trading volume of 2,682,578 shares, compared to its average volume of 2,095,139. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08. The company's fifty day moving average price is $15.75 and its two-hundred day moving average price is $19.74. The stock has a market cap of $1.71 billion, a PE ratio of 34.55, a P/E/G ratio of 1.64 and a beta of 1.31.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. During the same period last year, the firm posted $0.16 EPS. The company's revenue was up 2.0% on a year-over-year basis. Research analysts anticipate that Progyny, Inc. will post 0.59 EPS for the current year.

Insider Buying and Selling

In related news, CEO Peter Anevski acquired 209,500 shares of the stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now owns 441,463 shares of the company's stock, valued at $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of the company's stock in a transaction on Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now directly owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.